SCHEMBL3380156

SCHEMBL3380156

Cc1ccc(Nc2ncc(-c3cccnc3)c3cccnc23)nc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CKS1B P61024 6/20 0.47
SKP2 Q13309 6/20 0.47
CYP2A6 P11509 2/20 0.45
CYP3A4 P08684 1/20 0.45
DYRK1A Q13627 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
COMT P21964 1/20 0.40
MAPT P10636 2/20 0.39
HTT P42858 2/20 0.39
MAPK1 P28482 1/20 0.39
KDR P35968 1/20 0.38
NPC1 O15118 2/20 0.38
KMT2A Q03164 2/20 0.38
MAP2K4 P45985 1/20 0.37
MEN1 O00255 1/20 0.37
RAB9A P51151 1/20 0.37
PIM1 P11309 1/20 0.37
BRD4 O60885 1/20 0.36
ATAD2 Q6PL18 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3378893 0.86 CKS1B (0.42) CKS1BSKP2CYP3A4DYRK1AMAPT
SCHEMBL3378687 0.82 GRM5 (0.54) CKS1BSKP2CYP2A6
SCHEMBL3380124 0.81 CKS1B (0.42) CKS1BSKP2CYP2A6CYP3A4DYRK1A
SCHEMBL3379615 0.79 CKS1B (0.43) CKS1BSKP2DYRK1ADYRK1BPIM1
SCHEMBL13899832 0.79 CKS1B (0.42) CKS1BSKP2CYP2A6CYP3A4DYRK1A
SCHEMBL3379604 0.77 GRM5 (0.39) CYP2A6CYP3A4MAPTMAPK1
SCHEMBL3378927 0.76 MKNK1 (0.41) CYP3A4MAPTMAPK1
SCHEMBL3379022 0.76 GCK (0.51) CKS1BSKP2CYP2A6CYP3A4MAPT
SCHEMBL3379091 0.75 GRM4 (0.49) CKS1BSKP2DYRK1ADYRK1BKDR
SCHEMBL3378192 0.73 ABL1 (0.53) CYP3A4MAPTNPC1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101277958-B Naphthyridin derivatives HOFFMANN LA ROCHE 2011-09-07 CN claimed
EP-1934216-B1 NAPHTHYRIDIN DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP claimed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US claimed
CN-101277958-A Naphthyridin derivatives HOFFMANN LA ROCHE (CH) 2008-10-01 CN claimed
EP-1934216-A1 NAPHTHYRIDIN DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-06-25 EP claimed
WO-2007039512-A1 NAPHTHYRIDIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO claimed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US claimed
CN-101277958-B Naphthyridin derivatives HOFFMANN LA ROCHE 2011-09-07 CN disclosed
EP-1934216-B1 NAPHTHYRIDIN DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP disclosed
EP-1934216-B1 NAPHTHYRIDIN DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-11-24 EP disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
US-7511055-B2 Naphthyridin derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-31 US disclosed
CN-101277958-A Naphthyridin derivatives HOFFMANN LA ROCHE (CH) 2008-10-01 CN disclosed
EP-1934216-A1 NAPHTHYRIDIN DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-06-25 EP disclosed
WO-2007039512-A1 NAPHTHYRIDIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
WO-2007039512-A1 NAPHTHYRIDIN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-04-12 WO disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed
US-20070078155-A1 Naphthyridin derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070078155-A1 Naphthyridin derivatives GRM5, GRM3, GRM1 CKS1B 2655/4885SKP2 2843/4885CYP2A6 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.